Nirvana Life Sciences Past Earnings Performance
Past criteria checks 0/6
Nirvana Life Sciences's earnings have been declining at an average annual rate of -0.04%, while the Pharmaceuticals industry saw earnings growing at 67.6% annually.
Key information
-0.04%
Earnings growth rate
0.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Nirvana Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 0 | -1 | 1 | 0 |
| 31 Oct 23 | 0 | -1 | 1 | 0 |
| 31 Jul 23 | 0 | -2 | 1 | 0 |
| 30 Apr 23 | 0 | -1 | 1 | 0 |
| 31 Jan 23 | 0 | -6 | 1 | 0 |
| 31 Oct 22 | 0 | -6 | 1 | 0 |
| 31 Jul 22 | 0 | -6 | 1 | 0 |
| 30 Apr 22 | 0 | -6 | 1 | 0 |
| 31 Jan 22 | 0 | -1 | 0 | 0 |
| 31 Oct 21 | 0 | -1 | 0 | 0 |
Quality Earnings: NIRV is currently unprofitable.
Growing Profit Margin: NIRV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NIRV's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NIRV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NIRV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).
Return on Equity
High ROE: NIRV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.